Valuation: Alzinova AB

Market Cap 17Cr 1.75Cr 1.54Cr 1.43Cr 1.32Cr 2.47Cr 169Cr 2.51Cr 6.65Cr 83Cr 6.59Cr 6.45Cr 287.28Cr P/E 2026 *
-3.11x
P/E 2027 * -2.21x
Enterprise Value 15Cr 1.59Cr 1.4Cr 1.3Cr 1.19Cr 2.24Cr 153.12Cr 2.27Cr 6.03Cr 75Cr 5.97Cr 5.84Cr 260.28Cr EV / Sales 2026 *
4.92x
EV / Sales 2027 * -
Free-Float
82.23%
Yield 2026 *
-
Yield 2027 * -
1 day+12.00%
1 week+25.56%
Current month+69.35%
1 month+54.98%
3 months+85.02%
6 months+8.11%
Current year+1.33%
1 week 0.61
Extreme 0.61
0.84
1 month 0.48
Extreme 0.48
1.61
Current year 0.38
Extreme 0.382
1.61
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.7
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 69 01/01/2018
Director/Board Member 70 01/01/2020
Chairman 61 01/01/2023
Change 5-day change 1-year change 3-year change Capi.($)
+12.00%+25.56%-52.33%-75.40% 1.75Cr
+1.07%-3.49%-3.35%+10.44% 4.69TCr
+0.25%+1.65%+399.22%+634.87% 4.02TCr
-0.27%+4.45%+11.81%+65.64% 3.62TCr
+0.35%+0.87%+4.46%-10.16% 3.47TCr
+3.14%+1.02%+4.76%+40.92% 2.79TCr
-0.73%+11.84%+34.39%+134.36% 1.68TCr
+0.47%-2.74% - - 1.67TCr
+0.42%-5.52%-3.43%+9.03% 1.31TCr
-2.68%-2.49%-11.36%-33.61% 1.27TCr
Average +1.40%+3.30%+42.69%+86.23% 2.45TCr
Weighted average by Cap. +0.48%+0.91%+74.41%+136.26%

Financials

2026 *2027 *
Net sales 3.14Cr 32.32L 28.39L 26.4L 24.23L 45.52L 31Cr 46.22L 1.22Cr 15Cr 1.21Cr 1.19Cr 53Cr -
Net income -32L -3L -3L -3L -2L -5L -3.18Cr -5L -12.5L -1.56Cr -12.39L -12.12L -5.4Cr -5.04Cr -51.91L -45.59L -42.4L -38.91L -73.11L -50Cr -74.23L -1.97Cr -25Cr -1.95Cr -1.91Cr -85Cr
Net Debt -1.6Cr -16.5L -14.49L -13.47L -12.36L -23.23L -16Cr -23.59L -62.51L -7.81Cr -61.93L -60.59L -27Cr -1.9Cr -19.59L -17.21L -16L -14.68L -27.59L -19Cr -28.01L -74.23L -9.27Cr -73.54L -71.95L -32Cr
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
24/26/24 SEK 0.8400 +12.00% 30,16,369
23/26/23 SEK 0.7500 +7.45% 27,04,804
22/26/22 SEK 0.6980 +5.76% 56,98,218
21/26/21 SEK 0.6600 +0.15% 19,24,520
20/26/20 SEK 0.6590 -1.49% 13,60,375

Annual profits - Rate of surprise